Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Shares Outstanding (Weighted Average) (2020 - 2025)

SAB Biotherapeutics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $19.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 108.51% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $19.3 million, up 108.51%, while the annual FY2025 figure was $19.3 million, 108.51% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $19.3 million in Q4 2025 per SABSW's latest filing, up from $10.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $43.1 million in Q1 2022 to a low of $20860.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $15.7 million, with a median of $9.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 99.64% in 2022, then soared 3429.9% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $5.8 million in 2021, then tumbled by 99.64% to $20860.0 in 2022, then skyrocketed by 3429.9% to $736337.0 in 2023, then soared by 1157.84% to $9.3 million in 2024, then skyrocketed by 108.51% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Shares Outstanding (Weighted Average) are $19.3 million (Q4 2025), $10.7 million (Q3 2025), and $9.3 million (Q2 2025).